BioAlliance Pharma makes appointment

Judith Greciet put in charge of operations and r&d as deputy chief operating officer

BioAlliance Pharma, a French company dedicated to the supportive care and treatment of cancer patients, has strengthened its management team with the appointment of Judith Greciet as deputy chief operating officer, who takes charge of of operations and r&d.

Greciet joins the company from Eisai France, a company she managed as president for three years. Eisai France, with a €120m turnover, is focused on the Alzheimer’s disease field.

Greciet started at Eisai France in June 2007 after working for Wyeth Pharmaceuticals France (today Pfizer), French biopharmaceutical firm LFB Group, Zeneca and Pharmacia, where she held operational and strategic positions.

You may also like

Finance

Shareholders approve merger of BioAlliance Pharma and Topotarget

The combined business will be renamed Onxeo after completion of the transaction
Research & Development

Merger of BioAlliance Pharma and Topotarget to create new company called Onxeo

Transaction is expected to be completed in July/August
Finance

BioAlliance Pharma to merge with Topotarget

The companies have a pipeline of orphan oncology drugs
Manufacturing

BioAlliance Pharma collaborates with Penn Pharma on development of Validive

BioAlliance Pharma entrusts the pharmaceutical development of Validive to Penn Pharma, including the production of phase III clinical batches and the commercial production
Research & Development

BioAlliance receives ANR funding

To develop new applications of its mucoadheasive Lauriad technology
Drug Delivery

Ondansetron RapidFilm gains European approval

Suitable for children and adults with swallowing difficulties
You need to be a subscriber to read this article.
Click here to find out more.
Analysis

Semaglutide patent cliff: pharma industry braces for impact

With the weight-loss industry shifting from a monopoly held by innovators to a high-volume, competitive generic market, the pharma manufacturing sector is gearing up for a "generic wave" with investments into large-scale protein synthesis and facilities for injectables
Subscribe now